Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Large Is the Insulin biosimilars Market Expected to Be in 2029?

The market size for insulin biosimilars has seen a quick surge in the past few years. The market, which was valued at $3.04 billion in 2024, is predicted to reach $3.5 billion by 2025, reflecting a compound annual growth rate (CAGR) of 15.1%. Factors such as growing prevalence of diabetes, rising healthcare expenditures, increased access to diabetes therapies, competitive market environment, pricing pressures, along with regulatory backing and approval processes, have contributed to the growth witnessed in the historic period.

In the coming years, the insulin biosimilars market is predicted to experience swift expansion, escalating to “$6.04 billion in 2029 with a compound annual growth rate (CAGR) of 14.6%. Factors fueling growth in the forecast duration encompass expanding diabetes prevalence worldwide, developing markets and accessibility expansion, biosimilar acceptance regulations, preferences of patients for cost-effectiveness, and biopharmaceutical industry collaborations and partnerships. Key trends during the forecast period consist of diversification of insulin product ranges, global market infiltration, technological incorporation in insulin delivery, regulatory reinforcement for biosimilars creation, and patient-oriented tactics in product development.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10661&type=smp

What Are The Contributors To Demand In The Insulin biosimilars Market?

The insulin biosimilars market is anticipated to grow in response to the rising incidence of diabetes. This development in the insulin biosimilars market is driven by the diabetes epidemic, which is a set of prolonged metabolic disorders marked by elevated blood sugar levels. Biosimilars are critical in diabetes treatment because they offer an alternate insulin therapy option, thus the escalating incidence of diabetes amplifies the insulin biosimilars market demand. For example, by 2023, the National Center for Biotechnology Information, a U.S. government entity that disseminates biomedical and genomic information, expects the diabetes prevalence, which was 10.5% in 2021, to increase to 11.3% by 2030, and then to 12.2% by 2040. Therefore, the surge in diabetes prevalence is propelling the insulin biosimilar market.

The insulin biosimilars market covered in this report is segmented –

1) By Biosimilars Type: Rapid Acting biosimilars, Long Acting biosimilars, Premixed Acting biosimilars

2) By Disease Indication Type: Type I Diabetes, Type II Diabetes

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By End User: Hospitals, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Rapid Acting Biosimilars: Insulin Aspart Biosimilars, Insulin Lispro Biosimilars, Insulin Glulisine Biosimilars

2) By Long Acting Biosimilars: Insulin Glargine Biosimilars, Insulin Detemir Biosimilars, Insulin Degludec Biosimilars

3) By Premixed Acting Biosimilars: Insulin Aspart Protamine Biosimilars, Insulin Lispro Protamine Biosimilars, Biphasic Insulin Biosimilars

How Are Key Trends Driving Expansion In The Insulin biosimilars Industry?

Major firms in the insulin biosimilars market are advancing in the creation of interchangeable insulin to improve patient access, lower healthcare expenses, and provide consistent treatment outcomes for diabetes control. Interchangeable insulin plays a valuable role in the insulin biosimilars sector by encouraging therapy adherence and making treatments more affordable. For example, in April 2023, Eli Lilly, an American pharmaceutical firm, introduced Rezvoglar (insulin glargine-aglr), a biosimilar of insulin glargine targeting better glucose control for children and adult patients with Type 1 diabetes, as well as adults with Type 2 diabetes. Thanks to its interchangeable status, pharmacists can replace it with other insulin glargine prescriptions without requiring doctor’s approval, thus improving patient accessibility. This event establishes rezvoglar as the U.S.’s second interchangeable insulin biosimilar, strengthening both the competition and affordability in the insulin biosimilars market.

Who Are The Top-Ranked Companies In The Insulin biosimilars Market Today?

Major companies operating in the insulin biosimilars market include Eli Lilly and Company, Boehringer Ingelheim GmbH, Merck & Co Inc., Pfizer Inc., Biocon Ltd., Mylan N.V., Wockhardt Limited, NOVO Nordisk A/S, Sanofi S.A, Fresenius Kabi AG, Sandoz International GmbH, Novartis International AG, Aurobindo Pharma Ltd., Intas Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Ltd., Samsungbioepis Co. Ltd., Teva Pharmaceutical Industries Ltd., Stada Arzneimittel AG, Celltrion Inc., Fujifilm Kyowa Kirin Biologics Co. Ltd., Green Cross Corporation, Lupin Limited, Torrent Pharmaceuticals Ltd., Zydus Lifescience Ltd.

https://www.thebusinessresearchcompany.com/report/insulin-biosimilars-global-market-report

How Is Insulin biosimilars Market Adoption Varying Across Different Regions And Sectors?

North America was the largest region in the insulin biosimilars market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global insulin biosimilars market report during the forecast period. The regions covered in the insulin biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10661&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model